FIG. 6.
Selective Nox inhibitors. Over the past two decades our laboratory has developed 4 Nox isoform-specific inhibitors. (A) The peptide NoxA1ds specifically interrupts the complexation between NoxA1 and Nox1, with potential benefits of selective Nox1 inhibition in metabolic diseases listed. (B) At present, one peptide and two small-molecule inhibitors exist for Nox2. Nox2ds-tat mimics the Nox2-p47phox docking site inhibiting assembly and Nox2 superoxide production. The small-molecule inhibitors 11g and 11h are projected to fit into a p47phox binding pocket disrupting the interaction with p22phox and the assembly of the Nox2 isozyme specifically. Potential benefits of selectively inhibiting Nox2 in metabolic diseases are listed. Color images are available online.